Drug Profile
LFX 453
Alternative Names: LFX-453Latest Information Update: 01 Apr 2019
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Actinic keratosis; Genital warts
Most Recent Events
- 01 Apr 2019 Discontinued - Phase-II for Actinic keratosis in United Kingdom, Iceland, Denmark, Germany, Austria (Topical)
- 01 Apr 2019 Discontinued - Phase-II for Genital warts in USA (Topical)
- 01 May 2016 Novartis completes a phase-II trial in Genital warts in USA (NCT02482428)